CYTR News and Press, CytRx Corporation

LadRx Corporation (OTCQB: LADX) (“LadRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, Octo...

CytRx ( OTCQB:CYTR ) said it is renaming as LadRx Corporation, effective Sept. 26. The company added that it will trade under the ticker CYTR until the new symbol has been approved by FINRA LADR stands for Linker Activated Drug Release, a small organic backbone that ca...

The New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceut...

CytRx Corporation ( OTCQB:CYTR ) said on Wednesday it had been awarded a patent by the European Patent Office that covers the incorporation of the LADR backbone in a variety of drug compounds. The LADR backbone is attached to active pharmaceutical agents in orde...

Patent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has...

Mr. Claiborne Joined the CytRx Board of Directors as of the Annual Meeting CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcom...

KemPharm Sees Promise in Arimoclomol for Niemann-Pick Disease Type C, and Plans to Resubmit to FDA as Early as Q1 2023 CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and developmen...

Company Begins Planning First-in-Human Studies of Next-Generation LADR Drugs CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, toda...

Thanks Stockholders for Supporting Important Proposal at Recent Special Meeting CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, t...

CytRx (OTCQB:CYTR) said it is absorbing its subsidiary Centurion BioPharma to bring efficiency and simplicity to its structure. Centurion's assets — which consists of LADR platform being developed for localized delivery of cancer therapeutics — will be taken over by the company ...